论文部分内容阅读
目的:探讨细胞因子诱导杀伤(eytokine induced killer,CIK)细胞联合白细胞介素-2治疗恶性腹腔积液的临床疗效。方法:对65例患有恶性腹腔积液的患者实施引流术,研究组实施CIK细胞20ml配白细胞介素-2100万U灌注,检测3天;对照组实施顺铂35mg/m2和白细胞介素-2120万U灌注,坚持四周,每周灌注一次。据影像分析四次灌注后的效果。结果:研究组30例患者,有效26例,痊愈15例;对照组35例患者,有效24例,痊愈14例。研究组的毒副作用显著小于对照组,P<0.05。研究组的KPS评分显著高于对照组,P<0.05。且病种不同,显效也有差别,以腹腔积液合并肺癌、乳腺癌、卵巢癌和结直肠癌患者的治疗效果比较好,治疗后KPS评分也较对照组明显升高,中等分组上升也较多,低分组很少,毒副作用以低热和皮疹为主。结论:腹腔灌注CIK细胞配白细胞介素-2治疗恶性腹腔积液的效果显著,毒副作用小,安全可靠,在提高患者生活质量方面效果明显。
Objective: To investigate the clinical efficacy of eukaryotic induced killer (CIK) cells combined with interleukin-2 in the treatment of malignant ascites. Methods: Sixty-five patients with malignant ascites were treated by drainage. In the study group, 20ml CIK cells were infused with 20 million U / L interleukin-2 for 3 days. The control group received cisplatin 35mg / m2 and interleukin- 21.2 million U perfusion, adhere to the surrounding perfusion once a week. According to the image analysis of four perfusion results. Results: The study group of 30 patients, effective in 26 cases, 15 cases cured; control group of 35 patients, effective in 24 cases, 14 cases of recovery. The toxic side effects of the study group were significantly less than those of the control group, P <0.05. The study group KPS score was significantly higher than the control group, P <0.05. And the disease is different, markedly different, with ascites fluid combined with lung cancer, breast cancer, ovarian cancer and colorectal cancer patients treated better, KPS score after treatment was significantly higher than the control group, the middle group also more , Low grouping few, side effects with low fever and rash-based. Conclusion: CIK cells with peritoneal perfusion of interleukin-2 for the treatment of malignant ascites effusion significant effect, small side effects, safe and reliable, in improving the quality of life of patients with significant effect.